If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFrontier Ip Regulatory News (FIPP)

Share Price Information for Frontier Ip (FIPP)

Share Price is delayed by 15 minutes
Get Live Data
14.00    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 1.00 (7.407%)
Market Cap: £11.55m
FIPP Live PriceLast checked at - London Stock Exchange

Intraday Frontier Ip Share Chart

Exercise of Options & Total Voting Rights

14 Sep 2023 07:00

RNS Number : 3747M
Frontier IP Group plc
14 September 2023
 

AIM: FIPP

14 September 2023

 

Frontier IP Group Plc

("Frontier IP" or the "Group")

 

Exercise of Options, Issue of Equity

and

Total Voting Rights

 

Frontier IP, a specialist in commercialising intellectual property, announces that it has issued and allotted 47,000 ordinary shares of 10 pence each in the Group (the "New Ordinary Shares") following an exercise of 47,000 options on 13 September 2023. The options have been exercised as follows:

 

Grant Date

Number of Options

Exercise Price

11 May 2017

47,000

40 pence

 

The New Ordinary Shares have been issued pursuant to the exercise of options granted to an employee under the Frontier IP Group plc Employee Share Option Scheme 2011. The New Ordinary Shares rank, pari passu, in all respects with the Company's existing ordinary shares of 10p each ("Ordinary Shares"). 

 

Application has been made to the London Stock Exchange for the New Ordinary Shares to be admitted to trading on AIM. It is expected that admission of the 47,000 New Ordinary Shares to trading on AIM will become effective on, or around, 21 September 2023 ("Admission").

 

Total Voting Rights

Following Admission, the issued share capital of the Company will consist of 55,734,553 Ordinary Shares, with one voting right per share. The Company does not hold any Ordinary Shares in treasury. Therefore, the total number of Ordinary Shares and voting rights in the Company will be 55,734,553. From Admission, this figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

 

ENQUIRIES

 

Frontier IP Group Plc

T: 020 3968 7815

Neil Crabb, Chief Executive

Andrew Johnson, Communications & Investor Relations

Company website: www.frontierip.co.uk

 

neil@frontierip.co.uk

M: 07464 546 025

Allenby Capital Limited (Nominated Adviser)

Nick Athanas / George Payne

 

T: 0203 328 5656

Singer Capital Markets (Broker)

Harry Gooden / James Fischer

 

 

T: 0207 496 3000

 

ABOUT FRONTIER IP

Frontier IP unites science and commerce by identifying strong intellectual property and accelerating its development through a range of commercialisation services. A critical part of the Group's work is involving relevant industry partners at an early stage of development to ensure technology meets real world demands and needs.

 

The Group looks to build and grow a portfolio of equity stakes and licence income by taking an active involvement in spin-out companies, including support for fund raising and collaboration with relevant industry partners at an early stage of development.

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCGPUGWBUPWGMW
Date   Source Headline
11th Jul 20187:00 amRNSInnovate UK grant for Pulsiv Solar
19th Jun 20187:00 amRNSCambridge Material Testing Solutions
15th May 20187:00 amRNSPalintest launches Molendotech bathing water test
18th Apr 20184:09 pmRNSHolding(s) in Company
9th Apr 20188:25 amRNSIncreased Equity Holding in Fieldwork Robotics
27th Mar 20187:00 amRNSHALF-YEAR RESULTS, 6 MONTHS TO 31 DECEMBER 2017
26th Mar 20187:00 amRNSTeam Expansion and London Office
19th Feb 20187:00 amRNSPortfolio News - Molendotech Secures First Funding
29th Jan 20187:00 amRNSCapital Markets Day
29th Jan 20187:00 amRNSPortfolio News - Molendotech Collaboration
18th Dec 20177:00 amRNSCapital Markets Day
7th Dec 201711:50 amRNSResult of AGM
8th Nov 20177:00 amRNSPosting of Annual Report and Notice of AGM
30th Oct 20175:15 pmRNSHolding(s) in Company
30th Oct 201712:00 pmRNSPortfolio News PulsiV Granted Two US Patents
24th Oct 20177:00 amRNSFinal Results
9th Oct 20177:00 amRNSExscientia Wins Emerging Biotech Company Award
28th Sep 20177:00 amRNSExscientia announces investment from Evotec
25th Sep 20171:12 pmRNSHolding(s) in Company
20th Sep 20177:00 amRNSAlusid extends range at London Design Festival
7th Sep 20177:00 amRNSCSI launches novel sensor system at IFA Berlin
8th Aug 20177:00 amRNSNew Portfolio Company - The Vaccine Group
28th Jul 20173:26 pmRNSHolding(s) in Company
20th Jul 20177:00 amRNSPortfolio News- Nandi Proteins Limited Fundraising
11th Jul 20174:38 pmRNSHolding(s) in Company
5th Jul 20177:00 amRNSNew Portfolio Company - MolEndoTech
3rd Jul 20177:00 amRNSExscientia announces major GSK collaboration
11th May 20177:00 amRNSGrant of Options
9th May 201712:05 pmRNSRoyal Society of Chemistry Nominations
9th May 201711:25 amRNSExscientia announces major Sanofi collaboration
30th Mar 20177:00 amRNSHalf-Year Results for the 6 Months to 31 Dec 2016
24th Mar 20174:33 pmRNSHolding(s) in Company
23rd Mar 20173:27 pmRNSHolding(s) in Company
23rd Mar 20173:26 pmRNSHolding(s) in Company
23rd Mar 20173:25 pmRNSHolding(s) in Company
17th Mar 201712:10 pmRNSPlacing to raise £3 million
8th Feb 20177:00 amRNSChange of Adviser
23rd Dec 201611:45 amRNSResult of AGM
7th Dec 20167:00 amRNSNew Portfolio Company - Tarsis Technology Limited
28th Nov 20167:00 amRNSPosting of Annual Report and Notice of AGM
21st Nov 20167:00 amRNSAudited final results for year ended 30 June 2016
4th Nov 201611:00 amRNSALUSID Wins Prestigious IChemE Award
14th Sep 201611:50 amRNSAgreement with FCT, Universidade NOVA de Lisboa
5th Sep 20167:00 amRNSNandi Proteins Participant in £1m Funding Award
27th Apr 20167:00 amRNSex scientia Limited - Partnership with Evotec AG
11th Apr 20163:31 pmRNSHolding(s) in Company
7th Apr 20167:05 amRNSHolding(s) in Company
7th Apr 20167:00 amRNSGrant of Options
31st Mar 20168:30 amRNSHolding(s) in Company
30th Mar 20169:00 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.